
























B2B-Licensing

Product List (Q4 2022)

EU-GMP Dossiers available










| Active substance | Dosage form | Strength | Form | Indication |
|---|---|--|---|------------------------------------|
| 8-Methoxypsoralen (Oxsoralen®) | Ampoules ^{I/a/b} | 0.02 mg/ml (5 ml) |  | Cutaneous T-Cell Lymphoma |
| Acetylsalicylic Acid | Gastro-resistant tablets | 75 mg, 100 mg, 160 mg |  | Antithrombotic |
| | Tablets | 75 mg, 100 mg |  | |
| Benfotiamine | Film-coated tablets | 50 mg, 150 mg |  | Vitamin B ₁ Deficiency |
| | | 300 mg |  | |
| Buprenorphine | Sublingual tablets | 1 mg, 2 mg |  | Opioid Use Disorder |
| | | 4 mg, 6 mg, 8 mg, 12 mg, 16 mg |  | |
| Buprenorphine + Naloxone | Sublingual tablets ^{I/a/b} | 2 mg+0.5 mg, 4 mg+1 mg, 8 mg+2 mg |  | Opioid Use Disorder |
| Esketamine | Solution for injection or infusion ^{I/a/b} | 5 mg/ml (2 ml, 5 ml, 10 ml), 25 mg/ml (2 ml, 5 ml, 10 ml) |  | Severe Pain, Narcotic |
| | | 5 mg/ml (5 ml, 10 ml, 20 ml), 25 mg/ml (5 ml, 10 ml, 20 ml) |  | |
| Eslicarbazepine | Tablets | 200 mg, 400 mg, 600 mg, 800 mg |  | Epilepsy |
| Eszopiclone | Film-coated tablets ^{I/a} | 1 mg, 2 mg, 3 mg |  | Insomnia |
| Ethosuximide | Syrup ^{I/a/b} | 50 mg/ml (250 ml) |  | Epilepsy |
| Fe ²⁺ + Ascorbic Acid + Folic Acid (Ferretab® comp plus) | Capsules | 66.7 mg+100 mg+0.8 mg |  | Anaemia during Pregnancy |
| Fluoxetine | Film-coated tablets | 20 mg ^{I/a/b} |  | Depression |
| | | 40 mg | | |
| Folic Acid | Tablets | 1 mg, 5 mg |  | Folic Acid Deficiency |
| Hydromorphone | Solution for injection ^{I/a/b} | 2 mg/ml (1 ml), 10 mg/ml (1 ml, 10 ml) 20 mg/ml (1 ml), 50 mg/ml (1 ml) |  | Severe Pain |
| Hydroxocobalamine | Solution for injection | 1 mg/ml (1 ml) |  | Vitamin B ₁₂ Deficiency |
| Ketamine | Solution for injection or infusion ^{I/a/b} | 10 mg/ml (2 ml, 5 ml, 10 ml), 50 mg/ml (2 ml, 5 ml, 10 ml) |  | Severe Pain, Narcotic |
| | | 10 mg/ml (5 ml, 10 ml, 20 ml), 50 mg/ml (5 ml, 10 ml, 20 ml) |  | |
| Lacosamide | Film-coated tablets ^{I/a/b} | 50 mg, 100 mg, 150 mg, 200 mg |  | Epilepsy |
| | Oral solution | 10 mg/ml (200 ml, 500 ml) |  | |
| | Solution for infusion ^{I/a/b} | 10 mg/ml (10 ml, 20 ml) |  | |
| Levetiracetam | Oral solution | 100 mg/ml (150 ml, 300 ml) |  | Epilepsy |
| | Conc. for solution for infusion ^{I/a/b} | 100 mg/ml (5 ml) |  | |
| Levomethadone | Tablets ^{I/a/b} | 2.5 mg, 5 mg, 10 mg, 20 mg, 30 mg |  | Opioid Use Disorder |
| | Conc. for oral solution | 5 mg/ml (100 ml, 150 ml, 300 ml, 500 ml, 1000 ml) |  | |
| Metamizole | Solution for injection ^{I/a/b} | 500 mg/ml (2 ml, 5 ml) |  | Mild to Moderate Pain |

I/a/b: Zone I/a/b stability data available

| Active substance | Dosage form | Strength | Form | Indication |
|------------------------------------|--|--|---|-----------------------------------|
| Methadone | Tablets ^{Iva/b} | 5 mg, 10 mg, 20 mg, 40 mg, 60 mg |  | Opioid Use Disorder |
| | Conc. for oral solution | 10 mg/ml (100 ml, 150 ml, 300 ml, 500 ml, 1000 ml) |  | |
| Metoclopramide | Oral solution ^{Iva/b} | 1 mg/ml (150 ml) |  | Nausea, Emesis |
| | Solution for injection or infusion ^{Iva/b} | 5 mg/ml (2 ml, 10 ml) |  | |
| Morphine | Solution for injection ^{Iva/b} | 10 mg/ml (1 ml) |  | Severe Pain |
| | | 10 mg/ml (10 ml), 20 mg/ml (10 ml) |  | |
| Oxycodone | Film-coated tablets ^{Iva/b} | 5 mg, 10 mg, 20 mg |  | Severe Pain |
| | Prolonged-release tablets | 5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 60 mg, 80 mg |  | |
| | Oral solution ^{Iva/b} | 1 mg/ml (100 ml, 250 ml, 300 ml) |  | |
| | | 10 mg/ml (30 ml, 100 ml, 120 ml) |  | |
| Oxycodone + Naloxone* | Prolonged-release tablets | 5 mg+2.5 mg, 10 mg+5 mg, 20 mg+10 mg, 30 mg+15 mg, 40 mg+20 mg |  | Severe Pain |
| | | | | |
| Perampanel | Film-coated tablets ^{Iva/b}  | 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, 12 mg |  | Epilepsy |
| Potassium Iodide | Tablets | 65 mg |  | Radiation Prophylaxis |
| Tapentadol | Prolonged-release tablets ^{Iva/b} | 25 mg, 50 mg, 100 mg, 150 mg, 200 mg, 250 mg |  | Severe Pain |
| | Film-coated tablets ^{Iva/b}  | 25 mg, 50 mg, 75 mg, 100 mg |  | |
| | Oral solution ^{Iva/b}  | 20 mg/ml (100 ml, 200 ml) |  | |
| Tizanidine | Tablets ^{Iva/b} | 2 mg, 4 mg, 6 mg |  | Muscle Spasms |
| Trazodone | Oral solution ^{Iva/b} | 10 mg/ml (120 ml) |  | Depression |
| Valproic Acid/ Sodium Valproate | Oral solution ^{Iva} | 300 mg/ml (100 ml) |  | Epilepsy |
| Vitamin D ₃ | Oral solution ^{Iva/b} | 14 400 IU/ml (12.5 ml, 30 ml) |  | Vitamin D ₃ Deficiency |
| | | 28 800 IU/ml (12.5 ml, 30 ml, 50 ml) | | |

^{Iva/b}: Zone ^{Iva/b} stability data available / *No availability in the EU

Dossier update pending

| Active substance | Dosage form | Strength | Form | Indication |
|---|--|---------------------------------|---|---|
| Fe ²⁺ + Ascorbic Acid (Ferretab®) | Capsules | 100 mg+20 mg |  | Anaemia |
| Fe ²⁺ + Folic Acid (Ferretab® comp) | Capsules | 50 mg+0.5 mg |  | Anaemia during Pregnancy |
| Tramadol | Solution for injection | 50 mg/ml (2 ml) |  | Moderate to Severe Pain |
| | Oral drops | 100 mg/ml (10 ml, 30 ml, 50 ml) |  | |
| Valproic Acid/ Sodium Valproate | Gastro-resistant soft capsules ^{Iva} | 150 mg, 300 mg, 500 mg |  | Epilepsy |
| | Syrup ^{Iva} | 50 mg/ml (100 ml) |  | |
| | Solution for injection ^{Iva/b} | 100 mg/ml (5 ml) |  | |
| Vitamin B ₁ /B ₆ /B ₁₂ (Neuromultivit®) | Film-coated tablets | 100 mg+200 mg+0.2 mg |  | Vitamin B Deficiency, Neuropathic Pain |
| | Solution for injection | 50 mg+50 mg+0.5 mg/ml (2 ml) |  | |

Iva/b: Zone Iva/b stability data available

EU-GMP Dossiers under development

| Active substance | Dosage form | Strength | Dossier availability | Indication |
|------------------------------------|---------------------------|--|-------------------------|-----------------------|
| Brivaracetam | Film-coated tablets | 10 mg, 25 mg, 50 mg, 75 mg, 100 mg | 2024 | Epilepsy |
| Buprenorphine | Sublingual tablets | 0.2 mg, 0.4 mg | Q2 2023 | Opioid Use Disorder |
| Buprenorphine + Naloxone | Sublingual tablets | 1 mg+0.25 mg, 12 mg+3 mg, 16 mg+4 mg | Q4 2023 | Opioid Use Disorder |
| Candesartan + Chlortalidone | Tablets | 8 mg+12.5 mg, 16 mg+12.5 mg, 32 mg+12.5 mg, 32 mg+25 mg | 2024 | High Blood Pressure |
| Hydromorphone | Film-coated tablets | 1.3 mg, 2.6 mg | Q4 2023 | Severe Pain |
| Metamizole | Film-coated tablets | 500 mg, 1000 mg | Q4 2023 | Mild to Moderate Pain |
| Trazodone | Prolonged-release tablets | 75 mg, 150 mg | 2024 | Depression |
| Valproic Acid/ Sodium Valproate | Prolonged-release tablets | 300 mg, 500 mg | Q4 2023 | Epilepsy |

Zone Iva/b stability data planned for all products under development

Products protected by valid patents will not be offered for sale or supplied in countries where the respective patents are in force.
Please be advised that information on this list is subject to change. For markets with special requirements please check availability with our licensing managers.